Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 winsnews2026-01-30T16:04:43+00:00January 30th, 2026|Endpoints News|
AstraZeneca pays $1.2B for CSPC’s long-acting obesity drugsnews2026-01-30T10:36:16+00:00January 30th, 2026|Endpoints News|
Premise Health to merge with Crossover Health to expand employer clinicsnews2026-01-29T13:00:02+00:00January 29th, 2026|Endpoints News|
Following Abivax, Formation Bio licenses miR-124 drug from Chinanews2026-01-29T12:00:49+00:00January 29th, 2026|Endpoints News|
Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliffnews2026-01-29T11:46:10+00:00January 29th, 2026|Endpoints News|
Flagship’s Repertoire gets another autoimmune partner in Lillynews2026-01-29T11:30:20+00:00January 29th, 2026|Endpoints News|
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharmanews2026-01-27T15:40:01+00:00January 27th, 2026|Endpoints News|
Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcerenews2026-01-27T13:56:41+00:00January 27th, 2026|Endpoints News|
Lilly was the only pharma bidder for Ventyxnews2026-01-23T12:20:13+00:00January 23rd, 2026|Endpoints News|
Another biopharma tried buying Amicus before BioMarin’s $4.8B dealnews2026-01-22T15:16:22+00:00January 22nd, 2026|Endpoints News|
